US Cases / Year
~236k
~236,000 new cases/year; #1 cause of cancer death in men and women combined.[10]
What Is It
Definition, mechanism, and the clinical reality of lung cancer at end of life. What the hospice team needs to understand on day one.
NSCLC / SCLC Split
85/15%
85% NSCLC (adenocarcinoma, squamous, large cell); 15% SCLC. Different diseases. Different timelines. Different conversations.[2]
5-Year Survival
~28%
All stages combined. Stage I: 82–96%. Stage IV: single digits without targeted therapy.[5]
Hospice Median LOS
15–24 d
Among the shortest in oncology hospice. Late referral is the norm, not the exception. Every visit is a countdown.[9]
Lung cancer is the leading cause of cancer-related death in the United States and worldwide — accounting for more cancer deaths than breast, colon, and prostate cancer combined. It encompasses two biologically distinct diseases: non-small cell lung cancer (NSCLC), representing approximately 85% of all lung cancers, and small cell lung cancer (SCLC), representing 15%.[2][3]
NSCLC grows relatively slowly and includes several histologic subtypes — adenocarcinoma, squamous cell carcinoma, and large cell carcinoma — each with distinct molecular profiles and treatment targets. SCLC is a high-grade neuroendocrine carcinoma defined by rapid growth, early metastatic spread, and initial (but short-lived) chemosensitivity. These are not minor variants of the same disease — they behave differently, stage differently, and require entirely different management conversations.[2][3]
What makes lung cancer uniquely burdensome in hospice is the symptom profile: dyspnea is the dominant and most feared symptom, affecting patients and terrifying families who watch it. Dyspnea, cough, hemoptysis, pleural effusion, superior vena cava syndrome, and brain metastases can each demand urgent palliative intervention at any phase of illness.[9][36]
Key Epidemiology
- ~85% NSCLC, ~15% SCLC of all lung cancers[2]
- Leading cause of cancer death: men & women[10]
- 5-year survival all stages: ~25–28%[5]
- 70% of SCLC presents as extensive-stage at diagnosis[2]
- Median OS ES-SCLC: 12–13 months with modern therapy[6]
- Median OS stage IV NSCLC: 12–24 months with targeted/immunotherapy[19]
Why This Disease Is Different in Hospice
- Dyspnea is a primary, not secondary symptom — from early stages[36]
- SCLC trajectory is measured in weeks — rapid re-goals conversations[3]
- Brain mets in up to 50% of NSCLC — cognitive changes come before chart changes[27]
- TKI patients may have months of function, then crash fast[19]
- Temel 2010: early palliative care extended median survival 2.7 months[1]
🧭 Clinical Framing
Hospice median LOS for lung cancer is 15–24 days. That means most patients arrive far too late for the team to build the kind of relationship that makes the difference. When you get a new lung cancer referral, your first visit is also your most important one. You will not always get a second chance to have the hard conversation, prepare the family, or get the comfort kit in place.
"The first thing I do with every new lung cancer patient is ask about their breathing — not their pain, not their appetite. Dyspnea is what they go to bed dreading and wake up fighting. If you don't have a plan for it on day one, you don't have a plan."
— Waldo, NP · Terminal2
How It's Diagnosed
Diagnostic workup, staging, and what to look for in hospice records. Most patients arrive with an established diagnosis — this section helps you read it.
Diagnosis requires tissue confirmation via biopsy of a primary lung mass, thoracic lymph node, or metastatic lesion. CT chest/abdomen/pelvis, PET-CT, and brain MRI complete the staging workup. For NSCLC, next-generation sequencing (NGS) for molecular markers is now standard of care and critically affects both active treatment planning and palliative care conversations.[4][19]
NSCLC: TNM Staging (8th Ed.)
- Stage I–II: Localized; surgery ± adjuvant therapy potentially curative[4]
- Stage III: Locally advanced; concurrent chemoradiation ± immunotherapy[20]
- Stage IV: Metastatic; systemic therapy; hospice becomes relevant[14]
- 5-yr survival Stage I: 82–96% post-resection[5]
- 5-yr survival Stage III: 34–68%[5]
SCLC: Limited vs Extensive Stage
What to Look for in Hospice Records — Critical Molecular Testing (NSCLC Only)
- EGFR mutations (exon 19 del, L858R): ~15% of NSCLC; predictors of osimertinib response. Most common in never-smokers, Asian patients, adenocarcinoma.[19]
- ALK, ROS1, RET fusions; BRAF V600E; KRAS G12C; MET exon 14; HER2: All actionable with FDA-approved agents.[19]
- PD-L1 expression: Guides pembrolizumab eligibility; ≥50% = first-line monotherapy possible.[19]
- Hospice relevance: If a patient hasn't been tested, knowing mutation status may completely change goals. A TKI can restore months of functional living. Ask before finalizing comfort-only plans.
- ECOG performance status trend: What was ECOG 3 months ago vs now? Trajectory predicts timeline more reliably than snapshot.
💡 For families
Doctors use scans, biopsies, and blood tests to determine the type of lung cancer and how far it has spread. For one type (NSCLC), they also run tests looking for specific genetic changes — because certain targeted medicines only work for specific mutation types. Most of this workup is already complete by the time hospice begins. The focus is now entirely on comfort and quality of life.
Causes & Risk Factors
Modifiable and hereditary risk factors. Relevant for family conversations and answering "why did this happen?"
Cigarette smoking remains the dominant risk factor, implicated in 85–90% of SCLC and approximately 80% of NSCLC.[2][3] However, NSCLC in never-smokers — particularly adenocarcinoma with EGFR or ALK mutations — is a distinct and growing entity with a different biological profile and, often, a longer trajectory when targetable.[19]
Primary Causes
- Tobacco smoking: Pack-years strongest predictor; risk begins to fall ~10 years after cessation[2]
- Secondhand smoke: ~20–30% increased risk[9]
- Radon gas: Second leading cause of lung cancer in the US; odorless, colorless
- Occupational exposures: Asbestos (synergistic with smoking), arsenic, chromium, silica, diesel exhaust[9]
- Driver mutations (EGFR, ALK, KRAS): Oncogenic transformation independent of smoking in ~15–20% of NSCLC[19]
Risk Factors & Special Populations
- Age: Peak incidence 65–74; risk increases with advancing age[5]
- Family history: First-degree relatives with lung cancer increases risk ~2×[9]
- Black men: Higher incidence and mortality compared to white men, even at lower tobacco exposure levels — a documented disparity warranting explicit acknowledgment[10]
- Prior thoracic radiation: Lymphoma survivors at elevated risk
- SCLC molecular profile: Nearly universal TP53 + RB1 inactivation; EGFR testing rarely actionable[21]
- EGFR-mutant NSCLC → SCLC transformation: Occurs in 3–10% after TKI; responds to platinum-etoposide[21]
❤️ For families: "Why did this happen?"
Many families ask this — and in most cases, smoking played a role. But there is no room for guilt here. Some lung cancers have nothing to do with smoking. Others are driven by genetic changes, environmental exposures, or plain biology. This disease has been developing for years before any symptom appeared. What matters now is comfort, presence, and love.
⚕ Clinician note: Disparity awareness
Black men in the US have higher lung cancer incidence and mortality than white men at similar smoking exposure levels. This population is also more likely to be under-referred to palliative care and hospice. Name the disparity. Correct it where you can. Advocate within your system.
Treatments & Procedures
What patients may have received or may still be receiving. Understanding prior therapy helps anticipate complications and interpret the trajectory.
Lung cancer treatment has been transformed by targeted therapy and immunotherapy. Hospice and palliative care providers who know this landscape are better positioned to anticipate complications, manage side effects, and navigate goals-of-care transitions.[19][20]
NSCLC
Surgery & Radiation
Systemic: Targeted & Immunotherapy
- Osimertinib (EGFR+): Adjuvant and metastatic; CNS penetrant[19]
- Alectinib/brigatinib (ALK+): Excellent CNS activity[19]
- Pembrolizumab ± chemo: PD-L1 ≥1%; frontline standard[20]
- Sotorasib/adagrasib (KRAS G12C): 2nd-line after prior therapy[19]
- Trastuzumab deruxtecan (HER2): For HER2 exon 20 insertion[19]
SCLC
Limited Stage (LS-SCLC)
Extensive Stage (ES-SCLC)
- Platinum-etoposide + atezolizumab or durvalumab: First-line standard; median OS 12–13 months[6]
- Lurbinectedin: 2nd-line; 35% ORR; median PFS 3.7 months[2]
- Tarlatamab (DLL3 bispecific): 2nd-line; 40% ORR; novel mechanism[2]
- Relapse <3 months: Truly refractory; median survival 5–6 months with any salvage[25]
Palliative Procedures — Critical for Hospice NPs
Malignant Pleural Effusion
Brain Metastases
- SRS (stereotactic radiosurgery): ≤4 mets; brain control without WBRT neurotoxicity[53]
- WBRT: Multiple mets; high symptom burden; 1–3 month survival benefit[30]
- TKIs with CNS penetrance: Osimertinib, alectinib — may defer radiation[29]
- Dexamethasone: Rapid cerebral edema relief — essential comfort measure[9]
💡 For families
There are many ways to treat lung cancer — surgery, chemotherapy, radiation, pills that target specific gene changes, and medicines that help the immune system fight. Some procedures help relieve specific problems like fluid around the lungs or pressure in the brain. Your care team will explain which treatments are still appropriate and helpful given where things stand now.
When Therapy Makes Sense
Evidence-based criteria for continuing disease-directed therapy. Not about giving up or holding on — about reading the data correctly.
The landmark Temel 2010 NEJM trial demonstrated that early palliative care in NSCLC not only improved quality of life and mood — it extended median survival by 2.7 months compared to standard oncology care alone (11.6 vs 8.9 months).[1] This eliminates the false binary between "treatment" and "hospice." Concurrent, not sequential — always.[7]
- 01ECOG performance status 0–2: Patient tolerates active treatment; functional reserve exists. ECOG ≥3 dramatically shifts the risk-benefit calculation for most regimens.[18]
- 02Actionable driver mutation identified: EGFR, ALK, ROS1, KRAS G12C, and others offer oral targeted therapies with favorable toxicity profiles — restoring functional months even in late-stage disease.[19]
- 03
- 04First-line platinum-etoposide + immunotherapy in ES-SCLC: High initial response rates (60–70%) justify treatment even in extensive-stage disease when performance status permits.[6]
- 05Patient goals explicitly include life-prolongation: A well-informed patient who understands prognosis and chooses active treatment — having been given genuine prognostic clarity — should receive it without judgment or pressure toward hospice before they're ready.[7]
- 06Transition points not yet reached: First metastatic admission or first visceral metastatic site are defined NSCLC/SCLC transition triggers for palliative care integration — but not automatically for hospice enrollment.[14]
When It Doesn't
Evidence-based thresholds where continued disease-directed therapy no longer serves the patient. Knowing this is not failure — it is the highest clinical skill in this disease.
Despite strong evidence for early palliative care integration in lung cancer, underreferral remains the norm. In one Ontario cohort, 59% of dying lung cancer patients received palliative care a median of 27 days before death — and 55% died in hospital.[16] Knowing when treatment stops helping is not a clinical failure. It is the most important clinical skill in this disease.[13]
- 01ECOG performance status ≥3: Evidence consistently shows no survival benefit from chemotherapy at ECOG ≥3; treatment accelerates decline without meaningful response.[18]
- 02SCLC relapse within 3 months of first-line therapy: True resistance. Median survival with any salvage is 5–6 months. Treatment side effects typically outweigh benefit at this threshold.[25]
- 03Progression through two or more lines of systemic therapy (NSCLC without actionable mutation): Salvage response rates fall below 10–15%; toxicity dominates.[7]
- 04Extensive brain metastases / leptomeningeal carcinomatosis: Median survival 4–6 weeks from diagnosis of leptomeningeal disease regardless of treatment.[27]
- 05Severe cachexia and functional decline: Unintentional weight loss >10%, sarcopenia, BMI <18 — body cannot tolerate additional cytotoxic therapy.[49]
- 06
- 07Patient goals shift to comfort and home time: When a fully informed patient — who understands their prognosis — explicitly prioritizes quality over quantity, that is not giving up. It is clarity.[1]
Out-of-the-Box Approaches
Evidence-graded integrative and complementary approaches. Grade A = RCT; B = multi-observational/meta-analysis; C = limited clinical, strong preclinical; D = expert opinion.
The ACCP provides the most comprehensive evidence-based framework for integrative therapies in lung cancer. These approaches are adjuncts to — not substitutes for — pharmacological symptom management.[40][41]
Acupuncture / Acupressure (Dyspnea)
Grade A1–3× weekly; PC6, ST36, LU7 most studied for dyspnea and nausea
Phase II RCT of 173 lung cancer patients: acupuncture alone equivalent to morphine for dyspnea relief (74% vs 60% response); superior for anxiety reduction and morphine-sparing effect.[37] ACCP evidence-based guidelines support use for pain, nausea, and side effect management in lung cancer patients.[40] Minimal contraindications; thrombocytopenia warrants caution.
Therapeutic Exercise
Grade BIndividually tailored; group-based + at-home; 12-week programs studied
Multimodal program (exercise + nutrition + palliative care) demonstrated feasibility and significant reduction in tiredness with maintained QoL in advanced NSCLC.[39] ACCP guidelines support exercise as complementary to lung cancer care.[40] Benefit declines as ECOG worsens; adapt to current capacity.
Mind-Body Therapies (Meditation, Guided Imagery, Yoga)
Grade BDaily practice; 20–40 min; mindfulness-based stress reduction most studied
ACCP 2nd and 3rd edition guidelines document significant reductions in anxiety, mood disturbance, and psychological distress with mind-body modalities in lung cancer patients.[41][40] Particularly valuable when patients develop anxiety around dyspnea — reduces catastrophizing spiral. Safe across performance status levels.
Massage Therapy
Grade BSwedish or light effleurage; 30–60 min; 2–3× weekly
ACCP guidelines document reduction in pain, anxiety, and mood disturbance with massage in cancer patients including lung cancer.[41] Particularly meaningful for patients with dyspnea who feel fear in their body — touch de-escalates the respiratory panic response. Avoid deep tissue over bone mets, active thrombosis, or recent radiation fields.
Nebulized Opioids for Refractory Dyspnea
Grade CMorphine 5–20 mg nebulized; conflicting evidence vs systemic route
Dramatic anecdotal reports of dyspnea relief in hospice settings; however, randomized trials show conflicting results vs saline and oxygen — likely partly placebo/oxygen effect.[38] Systemic opioids (SQ/IV) have stronger evidence for dyspnea than nebulized route. Nebulized route remains an option when patient cannot swallow or refuses injection but should not replace systemic titration.
Traditional Chinese Medicine (TCM)
Grade CIndividualized; typically combined herbal formulas + acupuncture
Comprehensive 2025 review documents TCM's role in inducing cancer cell apoptosis, reversing drug resistance, inhibiting metastasis, and modulating immune responses in lung cancer.[43] Strong mechanistic basis — limited high-quality clinical trial data for most formulas. Discuss with pharmacist for TKI interactions.[42]
Natural & Herbal Options
Evidence grading, dosing where supported, drug interaction flags, and explicit contraindications specific to lung cancer. Patients will use supplements — this section is your conversation guide.
⚠️ TKI Interactions — Highest-Stakes Risk in Lung Cancer Herbal Use
Osimertinib, erlotinib, gefitinib, crizotinib, alectinib, and sotorasib are all CYP3A4 substrates. Any herb that strongly induces CYP3A4 — particularly St. John's Wort — will reduce TKI plasma levels by 50–90%, rendering treatment ineffective. Ask about supplements every single visit. The ACCP mandates screening for herbal/supplement use in all lung cancer patients.[41]
| Herb / Supplement | Evidence Grade | Typical Dose | Potential Benefit | ⚠ Interactions / Contraindications |
|---|---|---|---|---|
| 🌿 Astragalus (Huang Qi) | Grade B | 500–1000 mg BID-TID standardized extract | Immune support; macrophage polarization; synergistic cisplatin activity in preclinical models[45] | Mild CYP3A4 induction possible at high doses — monitor TKI levels. Warfarin monitoring if anticoagulated. Avoid in active immunosuppression (organ transplant). Caution with immunotherapy — theoretical immune overstimulation. |
| 🫚 Ginger (Zingiber officinale) | Grade B | 500–1000 mg TID for nausea; 250 mg QID during chemotherapy | Antiemetic (5-HT3 antagonism); gastric motility. Strong clinical evidence for CINV; relevant for disease-related nausea in hospice[40] | Mild antiplatelet effect — caution with NSAIDs or anticoagulants. Doses >4 g/day may have meaningful antiplatelet effect. Active GI bleeding or severe thrombocytopenia at higher doses: avoid. |
| 🌼 Curcumin (Curcuma longa) | Grade C | 500–1000 mg BID (phospholipid complex: Meriva/BCM-95) with food | Anti-inflammatory; pro-apoptotic via Wnt/β-catenin, PI3K/Akt/mTOR, NF-κB in lung cancer models[44] | Moderate CYP3A4 inhibition — may increase TKI plasma levels (unpredictable); inhibits CYP2C9 — monitor warfarin INR closely. May reduce platinum activity if taken within 4h of chemo. Active biliary obstruction: avoid. |
| 🍃 Panax Ginseng | Grade C | 200–400 mg/day standardized extract (≥5% ginsenosides) | Anti-tumor and immune-modulating via ginsenosides Rg1, Rb1; fatigue and QoL benefit claims (mixed evidence)[45] | Mild CYP3A4 modulation — monitor TKIs at higher doses. Additive antiplatelet effect with warfarin. Mild stimulant — may worsen anxiety in dyspneic patients. Bipolar disorder, insomnia, hypertension: avoid at high doses. |
| 🌱 Melatonin | Grade C | 3–20 mg orally at bedtime | Sleep quality; cancer-related fatigue; anti-tumor via apoptosis induction and immune modulation[43] | Additive sedation with opioids and benzodiazepines — dose opioids carefully when initiating. May affect CYP1A2 metabolism at high doses. Autoimmune disease: avoid (stimulates immune response). |
| 🍄 Medicinal Mushrooms (Reishi, Turkey Tail, Maitake) | Grade D | Reishi: 1.5–9 g/day whole or 1–2 g extract; Turkey Tail: 3 g/day | Beta-glucan polysaccharides; immunomodulatory; Turkey Tail (PSK/PSP) approved cancer adjunct in Japan[43] | Immunostimulatory — theoretical concern with immunosuppressants; unclear interaction with immunotherapy. Bleeding disorders (reishi has antiplatelet properties). Organ transplant recipients: avoid. |
🚫 Avoid in Lung Cancer — Contraindicated or High-Risk
- St. John's Wort (Hypericum perforatum): ABSOLUTE CONTRAINDICATION with TKIs. Potent CYP3A4 inducer reduces osimertinib, erlotinib, crizotinib, alectinib, and sotorasib plasma levels by 50–90%. Even "low dose" preparations maintain meaningful induction. Discontinue minimum 2 weeks before TKI initiation.[41]
- High-dose Vitamin E (>400 IU/day): Inhibits platelet aggregation; significantly increases hemorrhage risk in patients with hemoptysis or central/cavitating lung tumors. AVOID in any patient with hemoptysis history or high-risk tumor location.[40]
- Ginkgo biloba: Antiplatelet mechanism via PAF inhibition — meaningfully increases hemoptysis risk in patients with central tumors, vascular involvement, or thrombocytopenia. Avoid in all lung cancer patients with bleeding risk.[41]
- High-dose antioxidants during active chemotherapy (Vitamins C >1g, Beta-carotene): Evidence suggests interference with oxidative-stress-mediated tumor cell killing; ACCP and NCI advise against during platinum-based or anthracycline chemotherapy. Safe after completion.[40]
- Kava (Piper methysticum): Hepatotoxic; significant risk in patients receiving hepatically-metabolized chemotherapy or TKIs. Avoid entirely.[41]
- Comfrey (Symphytum officinale): Hepatotoxic pyrrolizidine alkaloids; contraindicated in all cancer patients, especially those with hepatic involvement.[41]
"Patients are going to use supplements whether we ask or not. With lung cancer, the stakes are especially high because of TKIs — so the conversation is direct: 'I need to know what you're taking, because some of these can make your cancer medication stop working entirely. Not hypothetically. Actually.' Say it plainly. Most of the time they're relieved someone asked."
— Waldo, NP · Terminal2
Timeline Guide
A guide, not a prediction. Every patient's trajectory is shaped by histology, molecular profile, treatment response, and comorbidities.
SCLC timelines are dramatically shorter than NSCLC. A patient with EGFR-mutant NSCLC on osimertinib may be stable for 18+ months; a patient with refractory SCLC relapse at 3 months may be in their final weeks. Use this guide accordingly — and update the family's mental model at every single visit.[2][6][25]
YRS–
MOS
MOS
Stage I–II NSCLC Post-Resection / LS-SCLC in Response
- Surveillance imaging every 3–6 months; fatigue, post-surgical dyspnea resolving
- TKI patients: excellent QoL, functional; rash, diarrhea, paronychia requiring management
- LS-SCLC with durvalumab consolidation: median OS now ~55.9 months (ADRIATIC)[22]
- Focus: restore function, monitor for recurrence, establish palliative care relationship, advance care planning
MOS–
1 YR
1 YR
Metastatic NSCLC on Targeted/Immunotherapy / ES-SCLC First-Line
- Median OS stage IV NSCLC: 12–24 months with modern systemic therapy[19]
- ES-SCLC median OS: 12–13 months; 60% relapse within 3 months of first-line[6]
- Symptoms: fatigue, intermittent dyspnea, cough, appetite decline, brain met risk rising
- Focus: symptom management, advance care planning deepens, early palliative care integration
WKS–
MOS
MOS
Progressive Disease / Hospice Transition
- NSCLC: progressive through ≥2 lines without actionable mutation; SCLC relapse <3 months
- Increasing dyspnea, cachexia, performance status decline to ECOG 3–4
- Brain mets increasingly symptomatic: personality change, word-finding, seizure risk[27]
- Focus: comfort kit preparation, IPC if pleural effusion, dexamethasone, opioid titration
DAYS–
WKS
WKS
Active Dying — Pre-Active Phase
- Bed-bound; minimal oral intake; sleeping most of day
- Dyspnea often worsening; requires around-the-clock opioid titration
- Respiratory secretions begin accumulating; position upright or semi-Fowler's
- Family teaching: fan on face reduces dyspnea perception; explain breathing changes; prepare for hemoptysis if high-risk tumor location[36]
HRS–
DAYS
DAYS
Final Hours
- Cheyne-Stokes or agonal breathing; mandibular breathing; mottling knees/feet
- Unresponsive or minimally responsive; auditory awareness may persist — speak to them
- Hemoptysis risk in some patients — prepare family well before this moment; midazolam 5 mg SQ must be drawn, labeled, and at the bedside before a hemoptysis event; dark cloth at bedside; family briefed on positioning
- If hemoptysis: dark red/brown cloth to absorb blood; position on bleeding side; stay present; speak calmly; midazolam immediately[9]
Medications to Anticipate
Symptom-targeted pharmacology for lung cancer hospice. What to have in the comfort kit, what to titrate first, and what the evidence supports.
Dyspnea is the dominant symptom driving medication decisions in lung cancer hospice. Morphine is the evidence-based first-line agent for dyspnea relief — via the systemic (SQ, PO, IV) route, not nebulized.[36][37] Brain metastases, SVC syndrome, and pleural effusion each require targeted pharmacological approaches alongside procedures.
| Drug | Class / Target Symptom | Starting Dose | Notes / Cautions |
|---|---|---|---|
| Morphine | Opioid / Dyspnea + Pain | 2.5–5 mg PO/SQ q4h; 2.5 mg q1h PRN dyspnea | Evidence-based for dyspnea via systemic route; titrate to effect. Nebulized opioids lack evidence — use systemic.[36] |
| Oxycodone | Opioid / Pain + Dyspnea | 5 mg PO q4–6h; 2.5–5 mg PRN | Alternative if morphine intolerance; no renal advantage over morphine.[9] |
| Dexamethasone | Corticosteroid / Brain edema, SVC, appetite | 4–8 mg PO/IV BID (brain mets); 2–4 mg QD (appetite) | Taper if using >2 weeks; glucose monitoring; proximal myopathy risk.[27] |
| Lorazepam | Benzodiazepine / Anxiety + Dyspnea | 0.5–1 mg PO/SQ q4–6h PRN | Evidence for anxiety component of dyspnea; use adjunctively with opioid, not instead of it.[36] |
| Midazolam | Benzodiazepine / Terminal agitation + Hemoptysis | 2.5–5 mg SQ PRN; 10–20 mg/24h SQ infusion | Essential for catastrophic hemoptysis. Midazolam 5 mg SQ must be drawn, labeled, and at the bedside before a hemoptysis event. Do not wait for the event to prepare it. |
| Glycopyrrolate | Anticholinergic / Terminal secretions | 0.2 mg SQ q4h; 0.6–1.2 mg/24h SQ infusion | Reduces secretions without CNS effects; preferred over hyoscine in conscious patients.[9] |
| Ondansetron | 5-HT3 Antagonist / Nausea | 4–8 mg PO/SQ q8h PRN or scheduled | QTc prolongation — check baseline ECG. Effective for chemo-related and disease-related nausea.[8] |
| Furosemide | Loop diuretic / Fluid overload, SVC | 20–40 mg PO/IV; adjust per response | May worsen intravascular depletion in cachectic patients; use judiciously.[35] |
| Guaifenesin | Expectorant / Cough | 200–400 mg q4h with adequate hydration | For productive cough in ambulatory patients; counterproductive in actively dying patients.[9] |
| Anamorelin | Ghrelin agonist / Cancer cachexia | 100 mg PO QD fasting | Increases appetite, body weight, lean mass in NSCLC cachexia; not widely available in all formularies.[47] |
🌿 Symptom Management Decision Tree
Evidence-based · Hospice-adaptedSelect a symptom below to begin
What is the primary symptom to address?
🚨 Comfort Kit Must-Haves for Lung Cancer — Hemoptysis Protocol
For patients with central tumors, cavitating lesions, or any prior hemoptysis: Midazolam 5 mg SQ must be drawn, labeled, and at the bedside before a hemoptysis event — not ordered for the event. Dark-colored towels visible at bedside. Family briefed on positioning (affected side down). Have this conversation at a calm visit. Document it in the chart. Say exactly what to do out loud: "If this happens, give the midazolam, turn them on this side, use this cloth, and call us immediately." Your calm preparation is the most therapeutic intervention available.[9]
Clinician Pointers
High-yield clinical pearls for the hospice team. Things learned at the bedside over years of clinical experience — not in the textbook.
1
The Temel trial is your clinical argument — use it
Early palliative care in NSCLC improved survival by 2.7 months AND improved QoL AND reduced aggressive end-of-life care. Keep this in your back pocket for every oncologist who says "let's wait." You are not pulling them toward death — you are extending living.[1]
2
Molecular testing before comfort conversations
If your patient hasn't had NGS testing, call oncology before finalizing the comfort plan. An EGFR exon 19 deletion or ALK fusion can mean 18+ months of functional living with oral targeted therapy. QoL far better than chemo. That call is always worth making.[19]
3
Dyspnea ≠ pain management — treat specifically
They share opioids but the mechanism is different. Dyspnea relief via morphine is likely central (μ-receptor), not peripheral. Titrate specifically for breathing distress — don't wait for pain to treat dyspnea. Fan on face, cool room (66–70°F), and upright positioning reduce subjective distress significantly.[36][37]
4
St. John's Wort is your most dangerous supplement in this disease
Patients on TKIs who add St. John's Wort lose 50–90% of TKI plasma levels. Never assume the patient knows this. Ask about supplements at every visit. The patient's oncologist may not have asked either.[41]
5
Brain metastases change families before they change the chart
Personality shifts, flat affect, word-finding difficulty, new hostility — these are brain mets until proven otherwise, not "end-of-life personality." Name it for the family before they blame themselves or each other: "This may be what happens when there's pressure in the brain from the cancer."[27][26]
6
SCLC vs NSCLC — a completely different timeline conversation
7
Advocate for IPC over repeated hospital thoracentesis
8
Cachexia is not starvation — set expectations early
It's a cytokine-driven metabolic syndrome that nutritional support alone cannot reverse. Setting expectations with families about appetite and weight loss is essential — and earlier than feels comfortable. Feeding does not fix cachexia in advanced cancer. This conversation is an act of kindness, not defeat.[49][48]
"Prepare for hemoptysis before it happens. For central tumors or cavitating lesions — have the conversation with the family at a calm visit, not in the middle of a crisis. Have midazolam drawn and labeled at the bedside. Dark cloth or towels visible. Know which side to position them on. Say it out loud. Your calm in that moment is the most therapeutic intervention available."
— Waldo, NP · Terminal2
Psychosocial & Spiritual Care
Existential distress, depression screening, spiritual assessment, and goals-of-care communication specific to lung cancer. The symptom burden you can't see on a vitals sheet.
Psychosocial and spiritual distress in lung cancer carries a specific character that separates it from most other diagnoses. Three things dominate: guilt around smoking history, fear of suffocation, and the unspoken goal of staying out of the hospital. Address all three directly, at every visit, before they fester into suffering you could have prevented.
Your job is not to provide the answers. Your job is to ask the questions that make space for the patient's own answers to emerge — and to connect them with the right people when they need more than you can offer.
Lung Cancer–Specific Psychosocial Themes
Guilt & Shame — Smoking History
Grade BPatients who smoked carry profound shame — often unspoken, often amplified by perceived social stigma. Research shows lung cancer patients are less likely to receive psychosocial support than other cancer patients, partly because caregivers unconsciously perceive self-causation.[12]
- Name it first: "Some patients feel guilty about their smoking history. I want you to know that what matters here is your comfort and your dignity — not how you got here."
- Addiction is a disease. Shame is not a clinical tool and does not belong in the hospice room.
- Never-smokers with lung cancer (15–20% of NSCLC) carry a different burden: bewilderment and anger. Acknowledge both reactions as valid.
- Screen for depression early — lung cancer patients have among the highest depression rates in oncology and are systematically undertreated.[11]
Fear of Suffocation — Address It Directly
Grade AFear of dying by suffocation is the most common death fear in lung cancer — documented across populations, cross-cultural, and nearly universal.[36][8] Patients and families rarely bring it up unprompted. You must ask.
- "A lot of patients with lung cancer are afraid that they'll have trouble breathing at the end. Is that something you're worried about?" — Ask it. Out loud. At a calm visit.
- The answer matters clinically: morphine controls dyspnea. Say that to them directly. Many patients have never heard this.
- Explain the mechanism: "We have medicines that change the way the brain perceives breathlessness. You won't feel like you're suffocating if we manage this well. That's our job."
- A fan on the face, a cool room, and upright positioning — teach these at enrollment, not at the crisis.
Goals of Care — What They Actually Want
When you ask lung cancer patients directly — without assumed answers — "staying out of the hospital" is almost universally the #1 stated goal. Not "more time." Not "more treatment." Home. Build every plan around this. Then ask what else matters.[1][7]
Opening the Conversation
- "What is your understanding of where things stand with your illness?" — assesses illness understanding before prognostic disclosure
- "What are you hoping for?" — surfaces values, not just preferences
- "What are you most afraid of?" — identifies what goals-of-care planning must address
- "If we do this right, what does a good day look like for you?" — orients the team around function and meaning, not just symptoms
- "Do you want to be at home when the time comes?" — say it plainly; most patients want to answer this question and haven't been asked
Communication Pitfalls
- Don't use language of surrender: "Stopping treatment" vs "shifting the focus of care"
- Don't say "there's nothing more we can do": There is always more to do — it just looks different now
- Don't have this conversation standing up: Sit down. Make eye contact. Leave silence. The patient will fill it.
- Don't wait for the family to be "ready": Waiting is not kindness. Preparation is.
- Involve the family separately when needed: Patients and families often have different goals — both need space to express them
Family Psychosocial — Secondhand Smoke Guilt
Family members who smoked around the patient — spouses, grown children, former coworkers — sometimes carry guilt they are terrified to name. Some families have never forgiven themselves. This will not surface unless you create the space for it. You do not need to resolve it. You need to name it, normalize it, and connect them with chaplain or social work.[11]
Clinical Pearl — Family Intervention
When a spouse or adult child is visibly withdrawn or over-controlling — check for guilt. Ask privately: "Sometimes family members feel like they played a role in what happened — from being around cigarette smoke or anything else. Is that something that's been on your mind?" The answer is almost always yes. The relief of being asked is immediate and profound.
Psychological Distress Screening
Depression — Screen Every Patient
Grade BSingle-question screen: "Are you depressed?" has 100% sensitivity in terminally ill populations when phrased directly.[7]
- PHQ-2: "Little interest/pleasure" + "Feeling down/hopeless" — score ≥3 warrants full PHQ-9
- Mirtazapine 7.5 mg QHS: First-line in hospice — addresses depression, insomnia, and anorexia simultaneously. Faster onset than SSRIs in this population.
- Distinguish depression from appropriate sadness — both deserve attention; only one warrants pharmacotherapy
- Lung cancer patients are undertreated for depression — be proactive, not reactive
Anxiety & Existential Distress
Grade B- Dyspnea-related anxiety: Often cyclical — anxiety worsens breathlessness; breathlessness worsens anxiety. Break the cycle with morphine + fan, not just benzodiazepines alone.
- Lorazepam 0.5 mg PRN for acute anxiety episodes — avoid scheduled use unless breakthrough is frequent
- Death anxiety specific to suffocation: Address this explicitly (see above). Reassurance without a concrete plan is not reassurance.
- Dignity therapy: Structured life narrative intervention — reduces suffering and increases sense of meaning[7]
- Refer to social work and chaplain at enrollment — not at crisis
Spiritual Assessment
Spirituality is not the same as religion. Patients with no religious affiliation still have spiritual needs — meaning, legacy, connection, peace. Use the FICA framework: Faith/beliefs, Importance, Community, Address. Ask: "What gives you strength during this time?" This opens spiritual conversation without assuming any tradition.[7]
- 01Ask about faith community explicitly: "Is there a faith community or spiritual leader who should know you're ill?" Don't assume — patients often won't volunteer this without being asked.[7]
- 02Involve chaplaincy at enrollment — not at crisis: Spiritual care is a clinical discipline. Chaplains are the experts. Your job is to open the door at admission, not when the patient is actively dying.
- 03Legacy and meaning work: "What do you most want your family to remember about you?" is both assessment and intervention. It shifts the conversation from dying to living.
- 04Unfinished business: Relationship ruptures, unresolved guilt, things left unsaid — these are clinical problems with real symptom burden. Don't leave them to chance.
"Lung cancer patients are afraid they'll choke. That's the thing they don't say out loud, and it's the thing that keeps them up at night. When I say 'We have medicine that takes away the feeling of breathlessness — you are not going to suffer through this,' and I mean it and they believe me — the whole room changes. That conversation is as therapeutic as any medication we carry. Have it early. Have it directly. Don't make them bring it up first."
— Waldo, NP · Terminal2
Family Guide
Plain language for families. Share, print, or read aloud at the bedside.
Lung cancer is among the hardest diagnoses to watch from the outside — partly because the breathing changes are visible, audible, and frightening. You are not watching your person suffer needlessly. Dyspnea is manageable. The care team has real tools for it.[11]
What You May See
- Breathlessness: Labored breathing even at rest; distress around breathing — this is the most common complaint. It looks worse than it usually feels when properly managed.[36]
- Cough: Persistent, sometimes productive; may have blood-tinged sputum. Call the nurse if you see bright red blood.
- Fatigue and weight loss: Even with eating — cancer changes how the body uses nutrition. This is not your failure. It is the disease.[49]
- Personality or mood changes: If cancer has spread to the brain, behavior and thinking may change. This is the disease — not your person.[27]
- Swelling of the face, neck, or arms: Can signal a problem with a vein near the heart (SVC syndrome) — call the nurse right away.
How You Can Help
- Fan on the face: A small bedside fan directed at the cheeks reduces the sensation of breathlessness significantly — even without changing oxygen levels. Keep it on low, aimed at the face.
- Position them upright: Head of bed elevated 30–45°; less work to breathe. Two or three pillows, or raise the head of the bed.
- Cool the room: Warmth worsens dyspnea; aim for 66–70°F / 19–21°C.
- Don't push food: Appetite loss is expected. Small, appealing offerings are enough. Forcing food causes suffering, not strength.[48]
- Be present without needing to fix things: Silence and touch are profoundly therapeutic. You do not need to say the right thing. Being there is the right thing.
📞 Call the nurse immediately if you see:
Sudden severe worsening of breathlessness · Coughing up significant bright red blood · New confusion or seizure · Face, neck, or arm swelling that develops rapidly · Inability to be woken · Sudden change in breathing rhythm or pattern · Any event that frightens you — call us. That is what we are here for.
🙏 You are doing something irreplaceable by being here. The data on lung cancer and palliative care is unambiguous: patients who have people present, who are not alone, who feel loved — they do better. Not just emotionally. Clinically. You are part of the treatment team whether you know it or not.
Waldo's Top 10 Tips
Clinical field wisdom from 12+ years at the bedside. Not guidelines — real.
- 01Dyspnea is the number one fear. Not death. The struggle to breathe. Address it at every single visit. Morphine works. The fan on the face works. Positioning works. Never walk out of a lung cancer visit without a specific, documented plan for breathing distress — not just "call if worse."
- 02Know your NSCLC from your SCLC. Same organ. Completely different disease. Different timeline, different conversations, different urgency. SCLC hits fast — families are not ready for how fast. NSCLC with a TKI can give someone functional, livable months. Don't treat them the same.
- 03The EGFR/ALK question is not academic. Before you finalize a comfort-only plan, make sure molecular testing has been done. I've seen patients who had never been tested — one phone call to oncology revealed an ALK fusion that gave them a year and a half of real living. That call is always worth making.
- 04St. John's Wort will silently kill a TKI. The patient won't know. The oncologist may not have asked. You need to be the one who asks. Every visit. Every time a new supplement appears on the medication list. CYP3A4 induction is not theoretical — it is a clinical event waiting to happen.
- 05Brain mets change the family before they change the chart. Watch for the flat look. The word they couldn't find. The irritability the spouse blames on depression or grief. Name it out loud: "This may be what happens when there's pressure in the brain from the cancer." It lands differently than a chart note.
- 06The Temel 2010 trial is in my back pocket at every oncology conversation. Early palliative care in NSCLC extended median survival by 2.7 months — not shortened it. 11.6 months vs 8.9 months. When someone tells me to wait until there's "nothing more to do," I pull that number out. Politely. Firmly.
- 07IPC over repeated hospital thoracentesis. When the pleural effusion keeps coming back and the prognosis is weeks to months, advocate for an indwelling pleural catheter. Patient goes home. Family drains it with training. They stop going to the hospital. That is a gift. Fight for it if you have to.
- 08SCLC patients decline in weeks, not months. Update the family's mental model at every visit. Not once. Every time. What was "six to eight weeks" two visits ago may already be "days to a couple of weeks." Don't let them wake up to a crisis they weren't prepared for. That's on us, not the disease.
- 09Cachexia is not starvation. I have watched families grieve themselves into exhaustion trying to get their loved one to eat — because the chart said "weight loss" and food feels like something they can control. It isn't. Cachexia is cytokine-driven. Feeding does not reverse it. Set that expectation early. It is an act of kindness.
- 10Prepare for hemoptysis before it happens. For central tumors or cavitating lesions — have the conversation with the family. Have midazolam drawn and labeled at the bedside. Dark cloth or towels visible. Know which side to position them on. Say it out loud at a good visit, not in the middle of a crisis. Your calm in that moment is the most therapeutic intervention available.
— Waldo, NP
References
54 peer-reviewed citations. Based on articles retrieved from PubMed. All PMIDs hyperlinked. Evidence levels assigned by article type.
1
Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363(8):733–742.
2
Kim SY, Park HS, Chiang AC. Small cell lung cancer: a review. JAMA. 2025;333(21):1906–1917.
3
Kalemkerian GP. Small cell lung cancer. Semin Respir Crit Care Med. 2016;37(5):783–796.
4
Schneider BJ. Non-small cell lung cancer staging: proposed revisions to the TNM system. Cancer Imaging. 2008;8(1):181–185.
5
Rajaram R, Huang Q, Li RZ, et al. Recurrence-free survival in patients with surgically resected NSCLC: systematic review and meta-analysis. Chest. 2024;165(5):1260–1270.
6
Zugazagoitia J, Paz-Ares L. Extensive-stage small-cell lung cancer: first-line and second-line treatment options. J Clin Oncol. 2022;40(6):671–680.
7
Smith TJ, Temin S, Alesi ER, et al. ASCO provisional clinical opinion: integration of palliative care into standard oncology care. J Clin Oncol. 2012;30(8):880–887.
8
Yao J, Novosel M, Bellampalli S, et al. Lung cancer supportive care and symptom management. Hematol Oncol Clin North Am. 2023;37(3):609–622.
9
Kvale PA, Simoff M, Prakash UBS. Lung cancer: palliative care. Chest. 2003;123(1 Suppl):284S–311S.
10
Shinde AM, Dashti A. Palliative care in lung cancer. Cancer Treat Res. 2016;170:225–250.
11
Ferrell B, Koczywas M, Grannis F, Harrington A. Palliative care in lung cancer. Surg Clin North Am. 2011;91(2):403–417.
12
Bade BC, Silvestri GA. Palliative care in lung cancer: a review. Semin Respir Crit Care Med. 2016;37(5):750–759.
13
Bhattacharya P, Dessain SK, Evans TL. Palliative care in lung cancer: when to start. Curr Oncol Rep. 2018;20(11):90.
14
Collins A, Sundararajan V, Burchell J, et al. Transition points for routine integration of palliative care in patients with advanced cancer. J Pain Symptom Manage. 2018;56(2):185–194.
15
Janssens A, Teugels L, Kohl S, et al. Integrating early palliative care in the management of lung cancer. Lung Cancer. 2015;90(2):135–138.
16
Wang Y, Van Dam A, Slaven M, et al. Resource use in the last three months of life by lung cancer patients in southern Ontario. Curr Oncol. 2019;26(4):247–252.
17
Nadolny S, Schildmann E, Gassmann ES, Schildmann J. What is "early palliative care"? A scoping review of controlled studies in oncology. Cancer Med. 2023;12(23):21335–21353.
18
Temel JS, Petrillo LA, Greer JA. Patient-centered palliative care for patients with advanced lung cancer. J Clin Oncol. 2022;40(6):626–634.
19
Gálffy G, Morócz É, Korompay R, et al. Targeted therapeutic options in early and metastatic NSCLC: overview. Pathol Oncol Res. 2024;30:1611715.
20
Isaacs J, Stinchcombe TE. Neoadjuvant and adjuvant systemic therapy for early-stage non-small-cell lung cancer. Drugs. 2022;82(8):855–863.
21
Marcoux N, Gettinger SN, O'Kane G, et al. EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: clinical outcomes. J Clin Oncol. 2019;37(4):278–285.
22
Senan S, Okamoto I, Lee GW, et al. Design and rationale for ADRIATIC: phase III study of durvalumab ± tremelimumab after CRT for limited-stage SCLC. Clin Lung Cancer. 2020;21(2):e84–e88.
23
Canova S, Trevisan B, Abbate MI, et al. Novel therapeutic options for small cell lung cancer. Curr Oncol Rep. 2023;25(11):1277–1294.
24
Reck M, Heigener D, Reinmuth N. Immunotherapy for small-cell lung cancer: emerging evidence. Future Oncol. 2016;12(7):931–943.
25
Gong J, Salgia R. Managing patients with relapsed small-cell lung cancer. J Oncol Pract. 2018;14(6):359–366.
26
Ernani V, Stinchcombe TE. Management of brain metastases in non-small-cell lung cancer. J Oncol Pract. 2019;15(11):563–570.
27
Achrol AS, Rennert RC, Anders C, et al. Brain metastases. Nat Rev Dis Primers. 2019;5(1):5.
28
Page S, Milner-Watts C, Perna M, et al. Systemic treatment of brain metastases in non-small cell lung cancer. Eur J Cancer. 2020;132:187–198.
29
Abdallah SM, Wong A. Brain metastases in non-small-cell lung cancer: are tyrosine kinase inhibitors and checkpoint inhibitors viable options? Curr Oncol. 2018;25(Suppl 1):S103–S114.
30
Zabel A, Debus J. Treatment of brain metastases from non-small-cell lung cancer: radiotherapy. Lung Cancer. 2004;45(Suppl 2):S247–252.
31
Mallow C, Hayes M, Semaan R, et al. Minimally invasive palliative interventions in advanced lung cancer. Expert Rev Respir Med. 2018;12(7):605–614.
32
Asciak R, Rahman NM. Malignant pleural effusion: from diagnostics to therapeutics. Clin Chest Med. 2018;39(1):181–193.
33
Neragi-Miandoab S. Malignant pleural effusion, current and evolving approaches for its diagnosis and management. Lung Cancer. 2006;54(1):1–9.
34
Bertolaccini L, Viti A, Terzi A. Management of malignant pleural effusions in patients with trapped lung with indwelling pleural catheter. J Vis Surg. 2016;2:44.
35
Chow R, Simone CB, Rimner A. Management of malignant superior vena cava syndrome. Ann Palliat Med. 2024;13(3):620–626.
36
Ripamonti C. Management of dyspnea in advanced cancer patients. Support Care Cancer. 1999;7(4):233–243.
37
Minchom A, Punwani R, Filshie J, et al. A randomised study comparing acupuncture or morphine versus combination for dyspnoea in NSCLC and mesothelioma. Eur J Cancer. 2016;61:102–110.
38
Chandler S. Nebulized opioids to treat dyspnea. Am J Hosp Palliat Care. 1999;16(1):418–422.
39
Ester M, Culos-Reed SN, Abdul-Razzak A, et al. Feasibility of a multimodal exercise, nutrition, and palliative care intervention in advanced lung cancer. BMC Cancer. 2021;21(1):159.
40
Deng GE, Rausch SM, Jones LW, et al. Complementary therapies and integrative medicine in lung cancer: ACCP evidence-based clinical practice guidelines (3rd ed). Chest. 2013;143(5 Suppl):e420S–e436S.
41
Cassileth BR, Deng GE, Gomez JE, et al. Complementary therapies and integrative oncology in lung cancer: ACCP evidence-based clinical practice guidelines (2nd ed). Chest. 2007;132(3 Suppl):340S–354S.
42
Frenkel M, Slater R, Sapire K, Sierpina V. Complementary and integrative medicine in lung cancer: questions and challenges. J Altern Complement Med. 2018;24(9–10):862–871.
43
Xi Z, Dai R, Ze Y, et al. Traditional Chinese medicine in lung cancer treatment. Mol Cancer. 2025;24(1):57.
44
Imtiaz I, Schloss J, Bugarcic A. Phytoconstituents and their roles in lung and colorectal cancer signaling pathways. Biomolecules. 2025;15(3):380.
45
Chen Y, Bi L, Luo H, et al. Water extract of ginseng and astragalus regulates macrophage polarization and synergistically enhances DDP's anticancer effect. J Ethnopharmacol. 2019;232:11–20.
46
Dong KF, Huo MQ, Sun HY, Li TK, Li D. Mechanism of Astragalus membranaceus in the treatment of laryngeal cancer based on gene co-expression network and molecular docking. Sci Rep. 2020;10(1):11184.
47
Zhang H, Garcia JM. Anamorelin hydrochloride for cancer-anorexia-cachexia in NSCLC. Expert Opin Pharmacother. 2015;16(8):1245–1253.
48
Del Ferraro C, Grant M, Koczywas M, Dorr-Uyemura LA. Management of anorexia-cachexia in late stage lung cancer patients. J Hosp Palliat Nurs. 2012;14(6).
49
Kidd AC, Skrzypski M, Jamal-Hanjani M, Blyth KG. Cancer cachexia in thoracic malignancy: a narrative review. Curr Opin Support Palliat Care. 2019;13(4):316–322.
50
Servetto A, Di Maio M, Salomone F, et al. Analysis of phase III clinical trials in metastatic NSCLC to assess correlation between QoL results and survival outcomes. BMC Med. 2023;21(1):234.
51
Azzopardi M, Thomas R, Muruganandan S, et al. AMPLE-2 trial: multicentre randomised study of aggressive vs symptom-guided drainage via indwelling pleural catheters. BMJ Open. 2016;6(7):e011480.
52
Qureshi RA, Collinson SL, Powell RJ, Froeschle PO, Berrisford RG. Management of malignant pleural effusion associated with trapped lung syndrome. Asian Cardiovasc Thorac Ann. 2008;16(2):120–123.
53
Tamari K, Suzuki O, Hashimoto N, et al. Treatment outcomes using CyberKnife for brain metastases from lung cancer. J Radiat Res. 2015;56(1):151–158.
54
Aggarwal C, Borghaei H. Treatment paradigms for advanced non-small cell lung cancer at academic medical centers. Oncologist. 2017;22(6):700–708.
Evidence levels: RCT Randomized Controlled Trial | | Sys Review | Observational | Guideline | Review Narrative | Expert Opinion
terminal2.care content is for educational purposes and is not a substitute for clinical judgment. Based on articles retrieved from PubMed. © Terminal2 | terminal2.care
Private Notes
Session notes — not saved to any server. Clears when you close the tab.
Use this space for visit notes, clinical reminders, or patient-specific observations. This text is stored only in your browser session.